SAMHD1 and diffuse large B-cell lymphoma: Interestingly, on subgroup analysis, while low SAMHD1 expression did not show a significant benefit within low-risk DLBCL patients (IPI of 0–1; P= 02530), it was significantly beneficial in patients with moderate to high-risk disease (IPI = 2–5; P= 0.0012) (Figure 3C, D).